Neuren Pharmaceuticals Says Angelman Syndrome Drug Shows Promise in Trial; Shares Down 6%
Neuren Pharmaceuticals Says Angelman Syndrome Drug Shows Promise in Trial; Shares Down 6%
Neuren製藥表示，安吉爾曼綜合症藥物在試驗中顯示出有希望的成果；股價下跌6%
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊